SC
DYN icon

Samlyn Capital’s Dyne Therapeutics DYN Stock Holding History

Samlyn Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39M Sell
1,754,708
-167,835
-9% -$3.12M 0.63% 51
2026
Q1 		$34.9M Buy
1,922,543
+429,468
+29% +$7.41M 0.59% 52
2025
Q4 		$29.2M Buy
+1,493,075
New +$28.3M 0.47% 55

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Samlyn Capital's DYN Position: Q2 2026 in Review

Samlyn Capital reduced its Dyne Therapeutics (DYN) stake by 8.7% in Q2 2026, selling an estimated $3.12M and leaving 1,754,708 shares worth $39M. The position accounts for 0.63% of the portfolio, ranked #51.

Samlyn Capital first reported a position in DYN in Q4 2025 and has held it in 3 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Samlyn Capital held 1,754,708 shares of Dyne Therapeutics worth $39M as of Q2 2026.
  • Samlyn Capital sold 167,835 Dyne Therapeutics shares in Q2 2026, an estimated $3.12M.
  • Dyne Therapeutics made up 0.63% of Samlyn Capital's portfolio in Q2 2026, its #51 holding.
  • Samlyn Capital first reported a position in Dyne Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Samlyn Capital's 13F filing for Q2 2026, filed 14 Aug 2026.